Monoclonal Gammopathy of Renal Significance
4 clinical trials · Condition
◉ Watch Monoclonal Gammopathy of Renal Significance
| Record | Firm | Date |
|---|---|---|
| Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD (NCT06418477) | Peking University People's Hospital | 2024-06-15 |
| A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) (NCT06083922) | Memorial Sloan Kettering Cancer Center | 2023-10-16 |
| MGRS: Clinical-histological Features of a Multicenter Case Series (NCT05119309) | University of Milano Bicocca | 2021-07-15 |
| Diagnosis of MGRS in Patients With Paraproteinemias: Clinical, Anatomopathological and Pathophysiological Study (NCT03629561) | Academia Nacional de Medicina | 2019-02-23 |
Track Monoclonal Gammopathy of Renal Significance automatically
Every clearance here is in the API, with alerts when new ones post.